


SCARD Pool report for 01-01-2020 to 31-12-2020

| | | | |
|---------------------|-----------------------------|---------|---------|
| Participants | Doctors | 376 | |
| | Patients | 57,802 | |
| Specimens | New lesions | 109,720 | 85.66% |
| | Previously biopsied lesions | 18,370 | 14.34% |
| | Total lesions | 128,090 | 100.00% |

Breakdown of new versus previously biopsied specimens


| | |
|--|--------|
| Percentage of new lesions tested which were malignant | 62.14% |
| Percentage of Definitively excised lesions that were malignant | 80.00% |
| Lesions tested to find one melanoma (NNT) | 3.95 |
| Percentage of lesions tested for NMSC which were NMSC | 75.53% |
| Ratio of New BCCs : New Melanomas | 9:1 |

Accuracy
Diagnostic sensitivity

| | |
|-----------|------------------|
| Melanomas | 75.22% of 3,713 |
| All NMSC | 95.69% of 62,301 |
| BCCs | 91.08% of 33,564 |
| SCCs | 82.82% of 28,389 |

Positive predictive value



| | |
|-----------|------------------|
| Melanomas | 41.76% of 6,689 |
| All NMSC | 81.44% of 73,198 |
| BCCs | 41.76% of 73,198 |
| SCCs | 65.79% of 35,739 |

Adequacy
Percentage of definitively managed malignant cases where surgical margins were adequate

| | |
|---------------------------|------------------|
| BCC | 87.70% of 22,526 |
| IEC/Bowens disease | 77.15% of 8,483 |
| SCC | 86.82% of 8,041 |
| Keratoacanthoma | 90.56% of 996 |
| Melanoma - in situ | 75.57% of 2,501 |
| Melanoma - invasive | 72.59% of 591 |
| Melanoma - invasive > 1mm | 42.00% of 100 |
| Other malignant | 72.80% of 125 |

Lesion Breakdown
Histological Diagnosis

| | | |
|-----------------------------|--------|--------|
| BCC (unspecified type) | 114 | 0.10% |
| BCC - Superficial | 10,473 | 9.53% |
| BCC - Nodular/Solid | 18,591 | 16.92% |
| BCC - Aggressive | 4,386 | 3.99% |
| IEC/Bowens disease | 15,812 | 14.39% |
| SCC | 11,071 | 10.08% |
| Keratoacanthoma | 1,506 | 1.37% |
| Pinkus Fibroepithelioma | 16 | 0.01% |
| Merkel cell tumour | 13 | 0.01% |
| Other malignant | 154 | 0.14% |
| NMSC Metastasis | 3 | 0.00% |
| Melanoma - in situ | 2,729 | 2.48% |
| Melanoma - invasive | 735 | 0.67% |
| Melanoma - invasive > 1mm | 222 | 0.20% |
| Melanoma - metastasis | 27 | 0.02% |
| MELTUMP | 162 | 0.15% |
| Naevus - other | 6,773 | 6.16% |
| Naevus - dysplastic/Clark | 3,071 | 2.79% |
| Naevus - blue | 387 | 0.35% |
| Naevus - Spitz/Reed | 113 | 0.10% |
| Naevus - Compound | 10 | 0.01% |
| Solar keratosis | 10,082 | 9.18% |
| Solar lentigo | 1,301 | 1.18% |
| Seborrhoeic keratosis | 5,705 | 5.19% |
| Lentigo Simplex | 1 | 0.00% |
| Lichenoid keratosis (LPLK) | 2,069 | 1.88% |
| Dermatofibroma | 808 | 0.74% |
| Sebaceous gland hyperplasia | 257 | 0.23% |
| Benign cyst | 1,747 | 1.59% |
| Other benign | 7,601 | 6.92% |
| Histology Pending | 158 | 0.14% |



Procedures
Definitive Surgical Management used to exclude melanoma

| | | |
|-----------------------|-------|--------|
| Ellipse | 2,920 | 87.11% |
| Flap | 54 | 1.61% |
| Graft - SSG | 2 | 0.06% |
| Graft - FTSG | 12 | 0.36% |
| No Closure | 11 | 0.33% |
| Shave/Saucerisation | 58 | 1.73% |
| Curettage & Cautery | 17 | 0.51% |
| Liquid N2 freeze/thaw | 6 | 0.18% |
| PDT | 0 | 0% |
| Imiquimod | 0 | 0% |
| 5 FU cream | 1 | 0.03% |
| GP referral | 180 | 5.37% |
| Specialist referral | 77 | 2.30% |
| Other | 7 | 0.21% |

Biopsy used to exclude melanoma

| | | |
|-----------------|-------|--------|
| Punch - sample | 655 | 5.51% |
| Shave - sample | 1,311 | 11.02% |
| Incisional | 229 | 1.92% |
| Punch - removal | 2,174 | 18.27% |
| Shave - removal | 2,704 | 22.73% |
| Excisional | 4,726 | 39.72% |
| Curettage | 44 | 0.37% |
| Other | 54 | 0.45% |

Breakdown of definitive management procedures for malignant conditions

| | | |
|-----------------------|--------|--------|
| Ellipse | 37,134 | 64.02% |
| Flap | 5,387 | 9.29% |
| Graft - SSG | 366 | 0.63% |
| Graft - FTSG | 1,311 | 2.26% |
| No Closure | 249 | 0.43% |
| Shave/Saucerisation | 1,012 | 1.74% |
| Curettage & Cautery | 6,904 | 11.90% |
| Liquid N2 freeze/thaw | 688 | 1.19% |
| PDT | 84 | 0.14% |
| Imiquimod | 513 | 0.88% |
| 5 FU cream | 941 | 1.62% |
| GP referral | 923 | 1.59% |
| Specialist referral | 1,759 | 3.03% |
| Other | 159 | 0.27% |

Breakdown of definitive management procedures for benign conditions

| | | |
|-----------------------|-------|--------|
| Ellipse | 5,148 | 76.18% |
| Flap | 91 | 1.35% |
| Graft - SSG | 2 | 0.03% |
| Graft - FTSG | 9 | 0.13% |
| No Closure | 43 | 0.64% |
| Shave/Saucerisation | 378 | 5.59% |
| Liquid N2 freeze/thaw | 218 | 3.23% |
| 5 FU cream | 116 | 1.72% |
| GP referral | 81 | 1.20% |
| Specialist referral | 35 | 0.52% |
| Other | 92 | 1.36% |

Procedures (continued)

Percentage of procedures/closures that were complex

| | |
|--|------------------|
| Complex Closures | 11.63% of 64,918 |
| Complex Closures (inc Curettage & Cautery) | 10.43% of 72,340 |

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

| | | |
|---------------|------|-----------------|
| Nose | 33 | 0.51% of 6,463 |
| Lip | 5 | 0.29% of 1,697 |
| Ear | 99 | 2.02% of 4,909 |
| Eyelid | 7 | 0.69% of 1,010 |
| Other face | 315 | 1.76% of 17,940 |
| Scalp | 101 | 2.27% of 4,456 |
| Neck | 139 | 2.45% of 5,683 |
| Shoulder | 257 | 5.06% of 5,081 |
| Chest | 179 | 2.73% of 6,563 |
| Abdomen | 97 | 6.58% of 1,474 |
| Genitalia | 1 | 0.64% of 157 |
| Back | 1234 | 8.04% of 15,349 |
| Buttock | 7 | 2.56% of 273 |
| Arm | 429 | 6.62% of 6,480 |
| Forearm | 209 | 2.62% of 7,965 |
| Hand Dorsal | 7 | 0.15% of 4,578 |
| Hand Palmar | 0 | 0% of 30 |
| Finger Dorsal | 0 | 0% of 965 |
| Finger Nail | 1 | 4.76% of 21 |
| Finger Palmar | 0 | 0% of 15 |
| Thigh | 200 | 6.00% of 3,334 |
| Leg | 361 | 2.67% of 13,519 |
| Foot Dorsal | 21 | 1.94% of 1,085 |
| Foot Plantar | 5 | 5.43% of 92 |
| Toe Dorsal | 3 | 1.97% of 152 |
| Toe Nail | 0 | 0% of 15 |
| Toe Plantar | 1 | 5.00% of 20 |
| Palm Or Sole | 0 | 0% of 0 |

